




RealRate

PHARMACEUTICAL 2019

Evoked Pharma Inc
Rank 267 of 363





RealRate

PHARMACEUTICAL 2019

Evoke Pharma Inc Rank 267 of 363



The relative strengths and weaknesses of Evoke Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evoke Pharma Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 36% points. The greatest weakness of Evoke Pharma Inc is the variable Net Income, reducing the Economic Capital Ratio by 110% points.

The company's Economic Capital Ratio, given in the ranking table, is -18%, being 54% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	5,648
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,634
Liabilities, Non-Current	0
Other Assets	12
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	449
Other Revenues	0
Property and Equipment	0
Research and Development	4,095
Selling, General and Administrative Expense	3,920

Output Variable	Value in 1000 USD
Assets	5,660
Liabilities	1,634
Expenses	8,015
Revenues	0
Stockholders Equity	4,025
Net Income	-7,566
Comprehensive Net Income	-7,566
Economic Capital Ratio	-18%